CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗中的活化诱导细胞死亡
英文原题：Activation-induced cell death in CAR-T cell therapy.
查看英文原题
Activation-induced cell death in CAR-T cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
表达肿瘤特异性嵌合抗原受体（CAR）的工程化T细胞对血液系统恶性肿瘤显示出显著疗效。然而，CAR-T 细胞治疗实体瘤的效果较差，主要原因是CAR-T 细胞持续存在能力不足，这可能与T细胞死亡有关。反复接受抗原刺激会显著诱导CAR-T 细胞发生活化诱导的细胞死亡（AICD）。T细胞AICD的特征包括死亡受体上调和T细胞持续存在能力降低。理解AICD机制对于提高CAR-T 细胞治疗实体瘤的抗肿瘤效果至关重要。研究者已采用多种CAR-T 细胞改造方法，以增强其抗凋亡能力。本文综述CAR-T 细胞AICD的分子机制以及CAR-T 细胞治疗中抗AICD研究的进展。
展开英文摘要原文
Engineered T cells expressing chimeric antigen receptors (CARs) with tumor specificity have shown remarkable therapeutic effects on hematologic malignancies.
However, CAR-T cells are less effective on solid tumors mainly due to the weak persistence of CAR-T cells, which might be caused by T cell death. Significant activation-induced cell death (AICD) of CAR-T cells was triggered by repeated antigen stimulation. AICD of T cell is characterized by the upregulation of death receptors and low persistence of T cells.
Understanding the mechanism of AICD is crucial to improve the anti-tumor effect of CAR-T cells against solid tumors. Many approaches have been applied in CAR-T cell modification to enhance their anti-apoptosis ability. In this review, we summarized the molecular mechanisms of AICD in CAR-T cells and the progresses of anti-AICD in CAR-T cells therapy.
论文信息
- 作者
- Huan T、Chen D、Liu G、Zhang H、Wang X、Wu Z、Wu Y、Xu Q
- 第一作者单位
- School of Life Sciences, Jiangsu University, 301 Xuefu Road, Zhenjiang, 212013, Jiangsu, China.China
- 通讯作者单位
- School of Life Sciences, Jiangsu University, 301 Xuefu Road, Zhenjiang, 212013, Jiangsu, China. yufeng@ujs.edu.cn.China
- 文献类型
- 综述
- 期刊
- Human cell2022 Mar
- 原文标识
- PubMed 35032297 · DOI 10.1007/s13577-022-00670-z